Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

BCMA Antibody-Drug Conjugate Reaches 60% Response in Myeloma

December 13th 2017

The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.

Elotuzumab/Lenalidomide Maintenance Deepens Responses After Transplant in Myeloma

December 13th 2017

Maintenance therapy with elotuzumab (Empliciti) and lenalidomide (Revlimid) after autologous stem cell transplant improves the quality of response achieved with induction therapy in patients with multiple myeloma.

Daratumumab Demonstrates Single-Agent Activity in Smoldering Myeloma

December 13th 2017

Daratumumab (Darzalex) displayed single-agent activity in intermediate- and high-risk smoldering multiple myeloma, according to results from the phase II CENTAURUS study.

Daratumumab Plus VMP New Standard of Care for Some Newly Diagnosed Myeloma Patients

December 12th 2017

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Dr. Gasparetto on Results for Selinexor and Daratumumab in Relapsed/Refractory Multiple Myeloma

December 11th 2017

Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting. Selinexor is an interesting new drug that inhibits Exportin 1 (XPO1), which reactivates some of the tumor suppressor proteins. In the phase 1b portion of the study, investigators aimed to identify the optimal dose of selinexor in combination with daratumumab. Gasparetto says the study included a small number of patients, but demonstrated very encouraging data.

Curative Approach Improves Responses in Patients With Smoldering Multiple Myeloma

December 11th 2017

A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

Case Study 2: Options for Biochemically Relapsed MM

December 8th 2017

Case Study 2: An Elderly Patient With Multiple Myeloma

December 8th 2017

Case Study 1: The Value of KRd in Multiple Myeloma

December 8th 2017

Case Study 1: Treating MM After RVd and Transplant

December 8th 2017

Case Study 1: Follow-Up Strategies for Multiple Myeloma

December 8th 2017

Case Study 1: A Diagnosis of Stage II Multiple Myeloma

December 8th 2017

Multiple Myeloma: Second Relapse and Beyond

December 8th 2017

Multiple Myeloma: Considerations in Treating Relapse

December 8th 2017

Multiple Myeloma: Using Novel Therapies at Relapse

December 8th 2017

Multiple Myeloma: Understanding and Treating Progression

December 8th 2017

Maintenance Therapy's Value in Multiple Myeloma

December 8th 2017

Multiple Myeloma: Optimizing Approaches to Transplant

December 8th 2017

The Current Role of Transplant in Multiple Myeloma

December 8th 2017